Vascular endothelial growth factor (VEGF) – a valuable serum tumour marker in patients with colorectal cancer?

Broll, R.; Erdmann, Heinrich; Duchrow, M.; Oevermann, E.; Schwandner, O.; Markert, Udo R.; Bruch, Hans–Peter; Windhövel, Ute

doi:10.1053/ejso.2000.1052

Cited by 68 publications

(50 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Details for each of these studies are given in Supplementary Table S1 for breast cancer (Yamamoto et al, 1996;Obermair et al, 1997;Salven et al, 1997Salven et al, , 1999bVerheul et al, 1997;Eppenberger et al, 1998;Adams et al, 2000;Foekens et al, 2001;Heer et al, 2001;Colleoni et al, 2002;Toi et al, 2002;Caine et al, 2003;Manders et al, 2003;Desruisseau et al, 2004;Granato et al, 2004;Sancak et al, 2004;Zhao et al, 2004;Bando et al, 2005;O'Riain et al, 2005), Supplementary Table S2 for prostate cancer (Joseph et al, 1997;Salven et al, 1997;Bauer et al, 1999;Duque et al, 1999;Jones et al, 2000;Bok et al, 2001;Figg et al, 2001;Caine et al, 2003Caine et al, , 2004Kohli et al, 2003;George et al, 2004;Kaushal et al, 2005;Li et al, 2005), Supplementary Table S3 for colorectal cancer (Dirix et al, 1996;Hyodo et al, 1998;Kumar et al, 1998;Baker et al, 2000;Chin et al, 2000;Davies et al, 2000;George et al, 2000;Broll et al, 2001;...…”

Section: Study Selectionmentioning

confidence: 99%

“…Studies on VEGF levels in urine (Bok et al, 2001), pleural effusion (Kraft et al, 1999;Thickett et al, 1999;Yanagawa et al, 1999;Kishiro et al, 2002;Toi et al, 2002), tumour cytosol (Obermair et al, 1997;Eppenberger et al, 1998;Baker et al, 2000;Broll et al, 2001;Foekens et al, 2001;Haraguchi et al, 2002;Toi et al, 2002;Manders et al, 2003;Desruisseau et al, 2004;Bando et al, 2005), tumour cyst fluid (Stockhammer et al, 2000) and other body fluids are available. However, most do not have a basis of comparison, as they report only the VEGF levels in cancer patients, but no control equivalent in healthy volunteers.…”

mentioning

confidence: 99%

“…Vascular endothelial growth factor levels in the normal colon tissues of cancer patients were evaluated (Baker et al, 2000;Broll et al, 2001). Vascular endothelial growth factor quantities in skeletal muscle (human vastus lateralis) (Gavin et al, 2004) and rat muscle, for comparison (Zhang et al, 1997) were also evaluated; muscle VEGF content is particularly important since it constitutes close to half the mass of the human body.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

2007

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human cancer. Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by measuring changes in VEGF concentrations in blood. In blood, the VEGF may be located in the plasma, or in the blood-borne cells and formed elements, in particular, platelets and leukocytes. In this study, we collate the measurements of VEGF in platelets, leukocytes, plasma and serum for breast, prostate, colorectal and other cancers. In addition, we analysed the concentration of VEGF in tumour tissue itself, as well as for other tissues in the human body. Although the concentration of VEGF in tumours is high, the size of tumours is small compared to other tissues, in particular, skeletal muscle. Thus, the total quantity of VEGF in tumours and in blood is small compared to the quantity in muscles. This large reservoir of VEGF may have important implications for the treatment of cancer.

show abstract

Section: Study Selectionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

2007

View full text Add to dashboard Cite

show abstract

“…numerous studies have indicated that VegF expression in tumor specimens is correlated with microvessel density, metastasis, tumor growth and poor prognosis in a variety of human solid cancer types including colorectal cancer (crc) (7,8). High preoperative serum or plasma VegF concentrations may predict poor prognosis in patients with crc (9,10). However, the values of VegF levels as biomarkers of anti-angiogenic therapy have yet to be established and require further evaluation (5,(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Aoyagi

Iinuma²,

Horiuchi³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. For individualized bevacizumab-based therapy, non-invasive biomarkers are necessary. this study assessed the predictive value of plasma vascular endothelial growth factor (VegF)-A, soluble VegF receptor (sVegFr)-1 and sVegFr-2 levels as biomarkers for clinical response and survival in advanced colorectal cancer (crc) patients treated with bevacizumab and modified FOLFOX6 (mFOLFOX6). Forty-six unresectable advanced crc patients and 20 healthy controls were included in this study. crc patients were treated with bevacizumab and mFOLFOX6. Pretreatment plasma VegF-A, sVegFr-1 and sVegFr-2 levels were measured using the multiplex immunoassay. Plasma VEGF-A, sVEGFR-1 and sVEGFR-2 levels were significantly higher in crc patients than in the healthy subjects. the plasma sVegFr-1 levels in the responder patients [complete response (CR)/partial response (PR)] and stable disease (SD) patients were significantly lower than those in the progressive disease (PD) patients (CR/PR vs. PD, p=0.025; SD vs. PD, p=0.032), while the plasma VegF-A and sVegFr-2 levels did not show any significant differences between the two groups of patients. Patients with higher sVEGFR-1 levels showed a significantly poorer progression-free survival (PFS) and overall survival (os) than those with lower VegFr-1 levels. In contrast, VEGF-A and sVEGFR-2 did not show any significant relationship between PFS and OS according to the status of each level. In the multivariate cox proportional hazard regression analysis, sVEGFR-1 levels showed a significant relationship between PFS and OS. These results suggest that plasma sVegFr-1 levels have a predictive value for clinical response and survival in advanced crc patients treated with bevacizumab and mFOLFOX6. Larger scale studies are needed to further validate our results.

show abstract

“…Total VEGF is not a sufficient diagnostic tool in patients with colorectal cancer because of poor sensitivity (36%) [8]. The ligands of the VEGF family include VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E [9].…”

Section: Introductionmentioning

confidence: 99%

Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients.

Myśliwiec¹,

Pawlak²,

Kukliński³

et al. 2009

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:Colorectal cancer growth and spread is absolutely dependent on angiogenesis with vascular endothelial growth factor (VEGF) being the most important cytokine involved in the process. Endoglin, a membrane co-receptor for TGF-β, has recently emerged as a sensitive index of cancer stage. There is now sufficient evidence indicating that microvessel density assessed by endoglin-immunostaining correlates with stage of colorectal cancer and patient survival. An association of a soluble form of endoglin with lymph node and distant metastases has recently been reported in two studies. Both of them used local elaborated immunoassays for endoglin assessment. The aim of our study was to determine the efficacy of plasma endoglin, assessed using a commercial kit, as a marker of tumor spread and distant metastases in colorectal cancer patients. We studied 48 colorectal cancer patients, compared with 22 healthy subjects, using ELISA. We observed that colorectal cancer patients had increased plasma VEGF-A, but not endoglin levels. However, we found an association of plasma endoglin with the stage of malignancy. Endoglin levels were increased in metastasis-positive patients when compared to both metastasis-negative patients and healthy volunteers. Plasma endoglin correlated with VEGF-A, CEA and CA19.9. Endoglin assessment in plasma does not seem useful as a maker of colorectal cancer. Our observations indicate however that it might be helpful in selecting patients with metastatic disease.

show abstract

Vascular endothelial growth factor (VEGF) – a valuable serum tumour marker in patients with colorectal cancer?

Cited by 68 publications

References 13 publications

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients.

Contact Info

Product

Resources

About